全文获取类型
收费全文 | 2551篇 |
免费 | 120篇 |
国内免费 | 15篇 |
专业分类
耳鼻咽喉 | 23篇 |
儿科学 | 44篇 |
妇产科学 | 10篇 |
基础医学 | 298篇 |
口腔科学 | 19篇 |
临床医学 | 164篇 |
内科学 | 769篇 |
皮肤病学 | 6篇 |
神经病学 | 184篇 |
特种医学 | 62篇 |
外科学 | 423篇 |
综合类 | 5篇 |
预防医学 | 56篇 |
眼科学 | 32篇 |
药学 | 180篇 |
中国医学 | 5篇 |
肿瘤学 | 406篇 |
出版年
2022年 | 16篇 |
2021年 | 36篇 |
2020年 | 30篇 |
2019年 | 25篇 |
2018年 | 29篇 |
2017年 | 22篇 |
2016年 | 28篇 |
2015年 | 32篇 |
2014年 | 53篇 |
2013年 | 79篇 |
2012年 | 114篇 |
2011年 | 120篇 |
2010年 | 61篇 |
2009年 | 47篇 |
2008年 | 111篇 |
2007年 | 147篇 |
2006年 | 127篇 |
2005年 | 121篇 |
2004年 | 142篇 |
2003年 | 145篇 |
2002年 | 187篇 |
2001年 | 55篇 |
2000年 | 57篇 |
1999年 | 78篇 |
1998年 | 55篇 |
1997年 | 55篇 |
1996年 | 52篇 |
1995年 | 42篇 |
1994年 | 53篇 |
1993年 | 40篇 |
1992年 | 51篇 |
1991年 | 35篇 |
1990年 | 37篇 |
1989年 | 42篇 |
1988年 | 26篇 |
1987年 | 39篇 |
1986年 | 40篇 |
1985年 | 46篇 |
1984年 | 24篇 |
1983年 | 21篇 |
1982年 | 12篇 |
1981年 | 17篇 |
1980年 | 13篇 |
1979年 | 13篇 |
1978年 | 20篇 |
1977年 | 15篇 |
1975年 | 15篇 |
1973年 | 8篇 |
1972年 | 9篇 |
1967年 | 6篇 |
排序方式: 共有2686条查询结果,搜索用时 296 毫秒
41.
Elevated expression of valosin-containing protein (p97) in hepatocellular carcinoma is correlated with increased incidence of tumor recurrence. 总被引:11,自引:0,他引:11
42.
Takeshi Tominaga Hiroki Koyama Tetsuya Toge Shigeto Miura Keizo Sugimachi Susumu Yamaguchi Koichi Hirata Yasumasa Monden Yasuo Nomura Masakazu Toi Izo Kimijima Shinzaburo Noguchi Hiroshi Sonoo Kazuaki Asaishi Tadashi Ikeda Tadaoki Morimoto Jun Ota Yasuo Ohashi Osahiko Abe 《Journal of clinical oncology》2003,21(6):991-998
PURPOSE: We compared the therapeutic usefulness of doxifluridine (5'-DFUR) alone and a combination of 5'-DFUR plus cyclophosphamide (CPM), both of which are considered effective against advanced and recurrent breast cancer, to determine which treatment is more beneficial as postoperative adjuvant chemotherapy. PATIENTS AND METHODS: A total of 1,131 women with node-positive primary breast cancer were randomly assigned after primary surgery to receive 5'-DFUR alone or 5'-DFUR plus CPM. All patients initially received 5'-DFUR in an oral dose of 1,200 mg/d for 4 weeks, starting 4 weeks after surgery. Chemotherapy was then not given for 2 weeks. Patients in the 5'-DFUR group subsequently received five 4-week cycles of treatment consisting of oral 5'-DFUR (1,200 mg/d) for the first 2 weeks and no chemotherapy for the next 2 weeks. Those assigned to the 5'-DFUR plus CPM group also received oral CPM 100 mg/d for the first 2 weeks and no chemotherapy for the next 2 weeks. Women 50 years or older concurrently received 20 mg/d of tamoxifen for 2 years in both groups. RESULTS: Of the 1,088 eligible women, 546 were assigned to receive 5'-DFUR alone and 542 were assigned to receive 5'-DFUR plus CPM. Overall disease-free survival was significantly better in women who received 5'-DFUR plus CPM than in those who received 5'-DFUR alone (log-rank test, P =.021). Toxic effects occurred in 20.0% of patients (109 of 546) in the 5'-DFUR group and 32.3% of patients (175 of 542) in the 5'-DFUR plus CPM group (chi(2) test, P <.001). CONCLUSION: Combination therapy with 5'-DFUR plus CPM is more effective in preventing recurrence than 5'-DFUR alone. 相似文献
43.
Yoshie Nakanishi Junichi Kodama Keizo Tokumo Noriko Seki Yasunari Miyagi Mitsuo Yoshinouchi Hiroyuki Okuda Takafumi Kudo 《International journal of clinical oncology / Japan Society of Clinical Oncology》1997,2(4):219-223
Background The object of this study is to clarify the association of an angiogenic factor, PD-ECGF (platelet-derived endothelial cell
growth factor/thymidine phosphorylase), with clinicopathologic factors, in this case tumor angiogenesis, in epithelial ovarian
cancers.
Methods Tumor specimens were obtained at the time of surgery from the primary lesion in 60 patients with epithelial ovarian cancer.
Histologic cell types were assigned to tumors according to the World Health Organization classification: 26 were classified
as serous adenocarcinoma, 15 as endometrioid adenocarcinoma, 9 as mucinous adenocarcinoma, 9 as clear cell carcinoma, and
1 as undifferentiated carcinoma. Surgical staging was based on the international Federation of Gynecology and Obstetrics (FIGO)
staging system: 16 were stage I, 6 were stage II, 34 were stage III, and 4 were stage IV. Expression of PD-ECGF was evaluated
by immunohistochemical staining. Microvessel density was assessed by immunostaining for factor VIII-related antigen in the
most neovascularized area.
Results Stroma cells stained more strongly than cancer cells (80% vs. 33%). The immunopositivity of PD-ECGF in stroma cells was higher
in cases of advanced cancer. Expression of PD-ECGF in mucinous adenocarcinomas was significantly higher than that in serous
adenocarcinomas, while PD-ECGF expression in clear cell carcinomas was significantly lower. The microvessel density in the
cases with marked PD-ECGF-positive stroma cells was significantly higher than that in the cases with absent/minimal PD-ECGF-positive
stroma cells (P<0.05).
Conclusion The expression of PD-ECGF may play a crucial role in the promotion of angiogenesis in epithelial ovarian cancers. 相似文献
44.
Allogeneic hematopoietic stem cell transplantation provides sustained long-term survival for patients with adult T-cell leukemia/lymphoma. 总被引:5,自引:0,他引:5
T Fukushima Y Miyazaki S Honda F Kawano Y Moriuchi M Masuda R Tanosaki A Utsunomiya N Uike S Yoshida J Okamura M Tomonaga 《Leukemia》2005,19(5):829-834
Adult T-cell leukemia/lymphoma (ATLL) is a distinct peripheral T-cell neoplasm that is highly resistant to chemotherapy. Several groups, including ours, have reported encouraging results of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for patients with ATLL. To confirm our previous report and to establish the basis for a phase II clinical study, we analyzed 40 allo-HSCT for acute and lymphoma types of ATLL in seven institutions in Japan between 1997 and 2002. All evaluable cases entered complete remission (CR) after allo-HSCT and the median survival time was 9.6 months for all patients. The estimated 3-year overall and relapse-free survival, and disease relapse were 45.3, 33.8 and 39.3%, respectively. Among 10 cases with ATLL relapse, five cases achieved CR again: three by the reduction or cessation of immunosuppressive agents, which suggested a graft-versus-ATLL (GvATLL) effect. However, univariate or multivariate analysis did not show any benefit of graft-versus-host disease (GVHD) on the prevention of relapse. These results suggested that allo-HSCT was effective for some patients with aggressive ATLL, and that the GvATLL effect could be achieved even without GVHD. A new phase II trial to test the efficacy of allo-HSCT for ATLL is warranted. 相似文献
45.
Jianhua He Yong Xu Daisuke Koya Keizo Kanasaki 《Clinical and experimental nephrology》2013,17(4):488-497
All types of progressive chronic kidney disease (CKD) inevitably induce renal fibrosis, the hallmark of which is the activation and accumulation of a large number of matrix-producing fibroblasts or myofibroblasts. The activated fibroblasts or myofibroblasts are derived from diverse origins, such as residential fibroblasts, vascular pericytes, epithelial-to-mesenchymal transition (EMT), and bone marrow (circulating fibrocytes). Recently, endothelial-to-mesenchymal transition (EndMT) or endothelial-to-myofibroblast transition has also been suggested to promote fibrosis and is recognized as a novel mechanism for the generation of myofibroblasts. Similar to EMT, during EndMT, endothelial cells lose their adhesion and apical–basal polarity to form highly invasive, migratory, spindle-shaped, elongated mesenchymal cells. More importantly, biochemical changes accompany these distinct changes in cell polarity and morphology, including the decreased expression of endothelial markers and the acquisition of mesenchymal markers. This review highlights evidence supporting the important role of EndMT in the development of renal fibrosis in CKD and its underlying mechanisms, including novel biological significance of microRNA regulation. 相似文献
46.
Analysis of factors predicting the response to tolvaptan in patients with liver cirrhosis and hepatic edema
下载免费PDF全文
![点击此处可从《Journal of gastroenterology and hepatology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Masanori Atsukawa Keizo Kato Hiroshi Abe Noritomo Shimada Toru Asano Tadashi Ikegami Mai Koeda Tomomi Okubo Taeang Arai Ai Nakagawa‐Iwashita Yuji Yoshida Korenobu Hayama Norio Itokawa Chisa Kondo Yoshimichi Chuganji Yasushi Matsuzaki Katsuhiko Iwakiri 《Journal of gastroenterology and hepatology》2018,33(6):1256-1263
47.
Diabetic nephropathy is the leading cause of progressive kidney disease, leading to end-stage renal disease and renal replacement therapy. Angiotensin-converting enzyme inhibitors and/or angiotensin receptor blockers have been considered effective at slowing the progression of kidney function deterioration. However, these drugs cannot sufficiently halt the progression of nephropathy to the extent that is required. A low-protein diet (LPD) is believed to be a nutritional intervention that may slow kidney disease progression. In fact, preclinical animal experiments have demonstrated excellent renoprotective effects of an LPD. However, in human clinical trials, analyses of the effects of protein restriction on diabetic nephropathy have not yet revealed consistently positive outcomes of this nutritional intervention. In this review, we analyze the potential renoprotective effects of an LPD on diabetic nephropathy and summarize the outcomes of clinical trials that have systematically investigated the efficacy of an LPD in diabetic nephropathy. In addition, we discuss some potential approaches associated with nutritional interventions to combat progressive kidney disease. 相似文献
48.
49.
Role of the spleen in liver fibrosis in rats may be mediated by transforming growth factor beta-1 总被引:13,自引:0,他引:13
Akahoshi T Hashizume M Tanoue K Shimabukuro R Gotoh N Tomikawa M Sugimachi K 《Journal of gastroenterology and hepatology》2002,17(1):59-65
BACKGROUND: The effect of the spleen on the cirrhotic liver is unknown. Transforming growth factor-beta 1 (TGF-beta 1), which plays a crucial role in the matrix production during liver fibrosis, is an inhibitory factor regarding the regeneration of hepatocytes. In this study, we investigated the TGF-beta 1 production in the spleen of cirrhotic rats and the effects of a splenectomy on the healing process from liver fibrosis. METHODS: Thirty-six Wistar male rats were used. Thioacetamide (TAA) was administered intraperitoneally for 24 weeks. The rats underwent either a sham operation (TAA + Sham) or a splenectomy (TAA + SPL). The improvements in liver fibrosis and liver regeneration were investigated 10, 30 and 60 days after the operations in each group. The effect of a splenectomy on the plasma concentration of TGF-beta 1 in the portal vein was investigated by ELISA. The TGF-beta 1 expressions in the spleen were measured using immunohistochemical staining and the degree of such expression was measured using RT-PCR. The activity of TGF-beta 1 in the portal vein of TAA + Sham and TAA + SPL was assessed by the inhibiting effect of rat parenchymal hepatocyte proliferation in primary culture. RESULTS: Liver regeneration (PCNA-labeling index) in the TAA + SPL rats was stimulated more at 10 and 30 days after the operation (P < 0.05) than in the TAA + Sham rats, and the improvement of liver fibrosis (fibrosis rate) in the TAA + SPL rats was higher at 60 days (P < 0.05) than in the TAA + Sham rats. The plasma concentration of TGF-beta1 of the portal vein in TAA + SPL rats was significantly lower than in the TAA + Sham rats for each period. Immunohistochemically, TGF-beta1-positive stained cells were recognized in the spleen macrophages in the red pulp of cirrhotic rats. The plasma of the TAA + Sham rats at 10 and 30 days after the operation was significantly stronger than that of the TAA + SPL rats in inhibiting the proliferation of rat hepatocytes of primary culture. Inhibitory effects were then dose-dependently neutralized by monoclonal TGF-beta 1 antibody. CONCLUSION: Spleen-derived TGF-beta 1 may thus play an inhibitory role in the healing of liver cirrhosis by inhibiting the regeneration of the damaged liver. 相似文献
50.
Suzuki R Miyazaki Y Takagi K Torii K Taniguchi H 《Treatments in respiratory medicine》2004,3(1):17-27
While asthma is an inflammatory disorder of the airways involving mediators released from mast cells and eosinophils, inflammation alone is insufficient to explain the chronic nature of the disease. Recent progress in the understanding of disease pathogenesis has revealed that airway remodeling, which is at least in part due to an excess of extracellular matrix (ECM) deposition in the airway wall, plays a significant role in airflow obstruction. Matrix metalloproteinases (MMPs) have been suggested to be the major proteolytic enzymes to induce airway remodeling in asthma and COPD. It has been widely accepted that different inflammatory processes are involved in asthma and COPD with different inflammatory cells, mediators, and responses to treatments. Despite these different processes, airflow obstruction and airway remodeling characterize these two diseases. MMP-2 and -9 have been reported to be involved in the pathogenesis of airway remodeling in both diseases and MMP-12, in addition to these MMPs, in the pathogenesis of COPD. In this review, we discuss the current views on the role of MMPs in the pathogenesis of bronchial asthma and COPD. Anti-MMP therapy could theoretically be useful to prevent airway remodeling in asthma and COPD. However, to date no clinical data are available regarding the efficacy of anti-MMP therapies in the treatment of patients with asthma and COPD. 相似文献